Thomas Kimble, MD
Obstetrics & Gynecology · Norfolk, VANPI 1649359993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $222,871 of the $285,581 with a category attached, or 78.0%. 5 manufacturers reported payments, led by AbbVie at 54.0% of the total. Reporting peaked in 2019 at $98,546 and has fallen 84.6% since, to $15,149 in 2025. Among obstetrics & gynecology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $1220.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$154K
- Exeltis, USA Inc.$51K
- Mayne Pharma Commercial LLC$34K
- Organon$33K
- Merck$13K
Across 236 payments — averaging $3201.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organon$217K
- Mylan Inc.$132K
- Sebela Pharmaceuticals Inc.$128K
- Medicines360$100K
- Bayer$53K
- Sebela Women's Health Inc.$39K
- plus $86K from 5 others
What the payments were for
- Consulting fees$44,75016%
- Speaking & faculty fees$222,87178%
- Travel & lodging$13,4775%
- Food & beverage$4,4832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 122 | $154,132 |
| Exeltis, USA Inc. | 14 | $51,320 |
| Mayne Pharma Commercial LLC | 32 | $34,269 |
| Organon | 42 | $32,572 |
| Merck | 24 | $13,288 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$102,527
- ORIAHNN$66,957
- Slynd$51,320
- NEXPLANON$45,067
- NEXTSTELLIS$26,636
- BIJUVA$8,398
- Nuvessa$8,000
- ANNOVERA$6,598
- SELECT-OB PLUS DHA$615
How this compares
$285,581 in reported general payments places this provider in the 95th percentile of 992 obstetrics & gynecology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 13 | $262 |
| Fluconazole | 21 | $83 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Norfolk
- Krystle LappinenNorfolk$20K
- Joseph HudgensNorfolk$18K
- Peter TakacsNorfolk$8K
- Jack AyoubLeesburg$279K
- Kurian ThottStafford$216K
- Nina SmithHarrisonburg$199K
- Joseph TroiseSalem$144K
- Bunan AlnaifChesapeake$139K
- James JonesRichmond$134K
- Melissa DelgadoVienna$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.